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Expression of transforming growth factor-fl and /32 in rat glomeruli.
The transforming growth factors-/3 are potent modulators of cell growth
and extracellular matrix metabolism in most types of cultured cells. The
distribution and functions of TGF-/3 in vivo are less well known. We
utilized several different techniques including northern blots, a CCI-64
cell growth inhibition assay, and sandwich enzyme-linked immunosor-
bent assays (SELISA) to examine the expression of TGF-/31 and
TGF-/32 in rat glomeruli. High levels of TGF-131 mRNA and protein
were found in glomeruli (56 22 ng TGF-/31/g tissue). These levels
were several-fold higher than those present in whole kidney (10 5
ng/g). TGF-/32 mRNA was present in glomeruli but was not detected in
whole kidney. TGF-f32 concentrations by SELISA were 19 8 ng
TGF-f32/g in glomeruli and less than 5 ng/g in whole kidney. Since
TGF-/3 has such marked effects on cell growth, we also examined
whether alterations in TGF-/3 expression were associated with the renal
hypertrophy which follows unilateral nephrectomy. Expression of
TGF-pl mRNA decreased in glomeruli following nephrectomy. How-
ever, this was not associated with a significant fall in glomerular
TGF-/31 protein concentration. Whole kidney levels of TGF-/31 and its
mRNA were unchanged following nephrectomy. Similar results were
obtained for TGF-f32. Our data document the presence of high concen-
trations of TGF-pl and /32 and their corresponding mRNAs in normal
rat glomeruli. These results suggest that TGF-/3 may play important
regulatory roles in the normal glomerulus.
The transforming growth factors-beta (TGF-13) are an ex-
panding family of homologous peptides which have diverse
effects on cultured cells. These effects have been most clearly
elucidated for TGF-/31 and include, among others, regulation of
cell proliferation and differentiation, and modulation of extra-
cellular matrix metabolism [1, 21. The distribution and roles of
TGF-3 in vivo are less well defined. TGF-f3 was found in tissues
of mouse embryos during critical periods of morphogenesis,
implying that an important role exists for TGF-f3 in embryogen-
esis [3]. TGF-13 has also been shown to accelerate wound
healing [4] and stimulate angiogenesis [5].
Based on the actions of TGF-f3 in vitro it seems reasonable to
suspect that TGF-/3 might be important in normal tissues at sites
where the regulation of extracellular matrix synthesis and cell
proliferation are critical to the maintenance of normal organ
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function. The glomerulus represents one such site, however,
recent studies using immunohistochemical techniques localized
TGF-/3 in the kidney only to the distal tubules; no glomerular
staining was found [6].
In the present study we examined the expression of both
TGF-/31 and TGF-/32 in glomeruli. TGF-/31 and 132 are 25,000
molecular weight homodimeric peptides which share 71% ho-
mology and possess identical biological activity in most assays
[2, 7]. At present the biological significance of these two forms
of TGF-f3 are not known, however, the demonstration of
preferential affinity of different receptors [8] for TGF-/31 and /32
suggest that unique roles may exist for these peptides.
We used a combination of northern blots, a CCI-64 growth
inhibition assay, and sandwich enzyme-linked immunosorbent
assays to assess levels of TGF-/31 and /32 and their mRNAs in
normal glomeruli. These levels were compared with those
present in whole kidney and renal papilla. Given the marked
effects of TGF-f3 on the regulation of cell growth, we also
evaluated the effect of unilateral nephrectomy on glomerular
TGF-/3 expression
Methods
Animals/glomerular isolation
Animals utilized in these studies were male Sprague-Dawley
rats weighing approximately 250 grams. Animals were allowed
free access to standard rodent chow and water. At the time of
sacrifice or nephrectomy animals were anesthetized with a
subcutaneous injection of Innovar-Vet (Pitman-Moore, Inc.,
Washington Crossing, New Jersey, USA).
Nephrectomies were performed via a left flank incision using
sterile technique. Glomeruli were isolated from the renal cortex
which was dissected free from the remainder of the kidney, cut
into small pieces and then gently pressed and rinsed through a
190 m sieve (E-C Apparatus Corp., St. Petersburg, Florida,
USA). After several additional passes through 190 sm sieves
the glomeruli were isolated on top of a 74 m sieve then gently
pelleted (25 g for 2 mm). These preparations contained > 90 to
95% glomeruli with <5 to 10% tubular fragments.
Northern blots
Whole kidney or portions of renal cortex or papilla, which
were dissected free from surrounding portions of the kidney,
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Fig. 1. Expression of TGF-/31 in rat kidney. Ten micrograms of total
RNA was fractionated on 1% agarose formaldehyde gels, transferred to
Nytran filters and probed with a single stranded TGF-13l probe. A. +:
2 zg of total RNA from porcine lymphocytes used as a positive control.
Abbreviations are: G, glomeruli; K, whole kidney; C, cortex; P, papilla.
The autoradiograph was exposed for 3 days. B. Ethidium bromide
stained gel used in panel A.
were homogenized in guanidine thiocyanate buffer and total
RNA isolated as described [9]. Each whole kidney and papilla
sample was derived from a single animal. Glomerular RNA was
isolated from glomeruli pooled from eight to ten animals. RNA
was quantitated based on its absorption at 260 nm. Ten micro-
grams of total RNA was fractionated on 1% agarose-formalde-
hyde gels and transferred to Nytran (Schleicher & Schuell,
Keene, New Hampshire, USA). Hybridization conditions were
those of Church and Gilbert [10]. The blots were hybridized in
a solution containing 1% bovine serum albumin, 7% SDS, 0.5 M
phosphate buffer pH 7.0, 10 mri EDTA, and 2 to 3 X 106 cpm
of labelled probe for 16 to 20 hours at 65°C. Blots were rinsed
three times for 10 minutes at room temperature in a solution of
0.5% BSA, 5% SDS, 40 m phosphate buffer and 10 mi
EDTA. Two or three stringent washes were then carried out
using a solution containing 1% SDS, 40 m phosphate buffer
and 10 mrvi EDTA for 10 minutes at 65°C. Blots were exposed to
Kodak X-Omat film for the indicated times, and then developed
in a Kodak X-Omat processor.
Probes were prepared as follows. A single stranded probe of
218 nucleotides was made by Klenow extension using a specific
oligonucleotide primer and 32P alpha-dCTP [11]. Details regard-
ing the construction of the Ml 3 clone containing the human
TGF-/3l cDNA are described by Van Obberghen and coworkers
[121. A single stranded probe from simian TGF-f32 cDNA [13]
was made from an M13 construct having a portion representing
both pro-region and the mature region of TGF-f32. The probe
was made using a specific oligonucleotide primer and extending
with Klenow fragment of DNA polymerase and 32P alpha-
dCTP, essentially as described [14]. A probe for glyceraldehyde
phosphate dehydrogenase (pRGAPDH-13) [15] used as a con-
trol hybridization was made by random primer labelling method
as described [16].
CCI-64 growth inhibition assay and SELISA
Kidneys were flushed free of blood then portions of whole
kidney or renal papilla were weighed and homogenized (Tis-
suemizer: Teckmar, Cincinnati, Ohio, USA) in acid-ethanol
(80% EtOH, 0.186 mti HC1, 50 g/ml PMSF). Two milliliters of
acid-ethanol was added to each 100 mg of tissue. Glomeruli
were isolated as described above and then weighed and acid-
ethanol added at the same weight/volume ratio. Kidney and
glomerular preparations were extracted overnight with rotation at
4°C. The preparations were cleared by centrifugation and stored at
—20°C until utilized. A CC1-64 mink lung epithelial cell growth
Fig. 2. Expression of TGF-/32 in rat kidney. Ten micrograms of total
RNA from papilla (P), whole kidney (K), and glomeruli (G) were
fractionated on 1% agarose formaldehyde gels transferred to Nytran
filters and probed with a single stranded TGF-fl2 probe. Two bands of
approximately 4.5 and 3.5 kb were evident. The autoradiograph repre-
sents a 7 day exposure. The ethidium bromide stained gel used for this
blot is also shown.
inhibition assay was performed as described by Danielpour and
co-workers [17], and as detailed in the legend to Figure 3.
For the SELISA, acid-ethanol extracts were lyophilized and
then resuspended in 4 m HCI, 0.1% bovine serum albumin.
Preparation of the affinity-purified rabbit and turkey antibodies
against TGF-13l and TGF-f32 which were utilized in this
SELISA are detailed by Danielpour and co-workers [18]. SELl-
SAs for TGF-/31 and TGF-132 were performed on these samples
exactly as described [18], except that levamisole (2 mM) was
added to the phosphatase substrate solution. Briefly, wells were
coated with affinity-purified rabbit anti-TGF-f31 or TGF-(32,
then washed in PBS containing 0.05% Tween 20, blocked with
Tris buffered saline containing 1% bovine serum albumin, and
washed again before test samples were added. Following a one
hour incubation at room temperature with test samples, wells
were washed and then coated with affinity-purified turkey
anti-TGF-f31 or anti-TGF-/32. Plates were incubated for one
hour at room temperature, washed, then incubated with phos-
phatase-linked goat anti-turkey IgG. Following this incubation
plates were washed and phosphatase substrate in ethanolamine
buffer with levamisole was added. The difference in absorbance
at 410 and 450 nm was measured with a Dynatech MR600
ELISA reader. Background absorbance was determined for
each sample in wells coated with pre-immune serum. TGF-/31
and /32 concentrations were determined by comparing the
absorbance of samples (after subtracting background) to a
log-log standard curve generated from absorbance readings of
known concentrations of TGF-f31 and TGF-f32.
Results
TGF-131 and (32 mRNA expression in normal rat kidney
Total RNA isolated from glomeruli, whole kidney, renal
cortex, and papilla were used to examine the expression of
TGF-/31 mRNA within the kidney. The 2.4 kb TGF-/31 tran-
script was found in all samples (Fig. 1). Glomeruli contained the
highest steady state level of TGF-f31 mRNA. By scanning
densitometry, levels were approximately four- to sixfold higher
A
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B
L
Fig. 3. CCI-64 inhibition assay. CCI-64 cells
were plated in 500 l of 0.2% FBS. Four hours
later additions were made to the wells as follows:
C:no additions, TGF-/3l: 0.1, 1.0 or 10 M TGF-
/31, GLO: glomerular extract, WK: whole kidney
extract, PAP: extract from renal papilla. Before
addition to the culture wells the tissue extracts
were diluted in PBS with 0.2% BSA. Fifty-five
microliters of these dilutions were added to the
culture wells to yield a final extract dilution of
1:100(1), 1:300 (3), or 1:900 (9). The hatched
bars labeled Ab indicate thymidine incorporation
in wells to which TGF-/31 (10 pM) or tissue
extracts (1: 100) were preincubated for 30 minutes
with TGF-/3 neutralizing antibody (120 tg/ml) (R
& D Systems, Minneapolis, Minnesota, USA).
After a 22 hour incubation, cells were labeled for
2 hours with 3H-TdR, harvested, and counted.
9 3 1 Ab 9 3 i Ab 9 3 i Ab Results are expressed as the mean SD of
preparations from three different animals. Each
GLO WK PAP preparation was assayed in duplicate.
We first utilized a biological assay for TGF-f3 to search for
TGF-f3 peptide in the kidney. In this assay acid-ethanol extracts
of glomeruli, whole kidney, or renal papilla were tested for their
ability to inhibit thymidine incorporation by CCI-64 cells, a cell
line which is very sensitive to growth inhibition by TGF-/3 [17].
The addition of glomerular extracts to CC 1-64 cells induced a
reduction in their incorporation of thymidine in a dose depen-
dent manner (Fig. 3). In contrast, thymidine incorporation in
wells treated with glomerular extract preincubated with TGF-f3
neutralizing antibody was significantly greater than that present
in control wells to which no additions were made. Addition of
extracts from whole kidney or papilla resulted in an increase in
thymidine incorporation which was minimally affected by pre-
incubation of the extracts with TGF-/3 neutralizing antibody.
SELISA for TGF-f31 and TGF-f32
A SELISA using antibodies specific for TGF-f31 and TGF-/32
[18] was utilized to confirm the presence of TGF-13, to quanti-
tate the peptide's tissue concentration, and to differentiate
TGF-f31 and TGF-/32. Glomerular extracts contained high
amounts of TGF-/3l (56 22 nglg tissue, mean SD, N = 7).
Much lower concentrations (10 5 nglg tissue, N = 4) were
found in whole kidney. Papilla contained an intermediate con-
centration of TGF-f31 (33 13 nglg tissue, N = 3). Tissue levels
of TGF-/32 determined by TGF-/32 specific SELISA revealed 19
8 ng of TGF-f32 per gram of glomerular tissue (mean SD, N
= 4). Whole kidney and papilla contained less than 5 ng of
TGF-/32 per gram of tissue.
Expression of TGF-f3 following nephrectomy
We first evaluated the effect of nephrectomy on TGF-f31 and
/32 mRNA expression. As shown in Figure 4, levels of both
Fig. 4. Glomerular expression of TGF-/31 and /32 and GAPDH mRNAs
following nephrectomy. Total RNA was isolated from rat glomeruli
before (0), or three (3), or seven (7) days following nephrectomy. RNA
was also isolated from rats seven days following sham nephrectomy (5).
Samples were fractionated on a 1% agarose formaldehyde gel, trans-
ferred to a Nytran filter and hybridized with probes for TGF-/3l (/31),
TGF-f32 (/32), and GAPDH (G). The filter was stripped after each
hybridization. Results comparable to those presented were obtained in
two independent experiments using different groups of animals. The
TGF-/31 probed filter was exposed for 4 days, TGF-/32 for 6 days, and
GAPDH for 16 hours. The ethidium bromide stained gel used for the
above blots is also shown.
TGF-j31 and TGF-f32 mRNA in glomeruli decreased following
nephrectomy. Of note is the decrease in TGF-f32 mRNA which
also occurred in animals subjected to sham nephrectomy. In
contrast to the findings for glomeruli, we detected no changes in
TGF-/31 or /32 mRNA expression in whole kidney or renal
papilla following nephrectomy or sham nephrectomy (data not
shown).
Since the results of northern analysis indicated that glomer-
ular TGF-/3 mRNA levels were lower at day seven than they
were at earlier time points, we chose the seven day time point
to assay TGF-f3 protein concentrations using the CCI-64 assay
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than those present in whole kidney. The renal papilla contained
an approximately twofold higher level of TGF-f3l mRNA than
was present in whole kidney. TGF-f32 mRNA, evidenced by
two bands of approximately 4.5 and 3.5 kb, was present in
glomeruli but was not detected in either whole kidney or renal
papilla (Fig. 2).
CC1-64 cell growth inhibition assay
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Fig. 5. Effect of nephreclomy on biologic
activity of acid ethanol extracts from
glomeruli and whole kidney. Acid-ethanol
extracts from glomeruli (GLO) or whole
kidney (WK) from unmanipulated rats (0) or
9 3 1 Ab those seven days following nephrectomy (7)
were compared using the CCI-64 assay
WK 7 described in the legend to Fig. 3.
GLO WK PAP
Fig. 6. Effect of nephrectomy on TGF-131 concentration. TGF-131 pro-
tein concentration was determined by SELISA on acid-ethanol ex-
tracted glomeruli (GLO), whole kidney (WK) and papilla (PAP) seven
days after nephrectomy (open bars) or sham nephrectomy (hatched
bars). Values are given as mean and standard deviation of the mean
(GLO N = 7, WK N =4, PAP N = 3).
and SELISA. We found no significant difference in thymidine
incorporation in cells exposed to extract from glomeruli or
whole kidney before or seven days following nephrectomy (Fig.
5). No significant differences in TGF-/31 protein concentration
determined by SELISA were found when animals subjected to
sham operations were compared to those subjected to unilateral
nephrectomy (Fig. 6). We also examined TGF-/3 peptide levels
by SELISA at eleven days following nephrectomy, reasoning
that falls in protein levels might follow the decrease in TGF-/31
mRNA expression. Again we found no significant change in
glomerular TGF-/31 levels eleven days following nephrectomy
or sham operation (npx 47 13, N = 6; sham 44 0, N = 3).
In addition, no difference in tissue levels of TGF-/32 in glomer-
uli, whole kidney and papilla were detected by TGF-j32 specific
SELISA in nephrectomized, sham operated, and unmanipu-
lated animals.
Discussion
In these studies we document the presence of high concen-
trations of TGF-f31 and /32 in normal rat glomeruli. We first
searched for TGF-/3 expression in the glomerulus using north-
ern analysis and found that glomerular TGF-/3l mRNA levels
were approximately sixfold higher than those present in whole
kidney. This result was somewhat surprising because recent
studies using immunohistochemistry failed to detect TGF-/3 in
the glomerulus [6]. We utilized two independent assays to
demonstrate the presence of TGF-/3 in the glomerulus. The first,
a CCI-64 growth inhibition assay, is an established biological
assay for TGF-13 [17]. The second assay was a SELISA for
TGF-/31 and TGF-/32. The SELISA allowed us to differentiate
TGF-/31 and TGF-/32 and to quantitate both peptides.
The concentration of TGF-13l within the glomerulus (56 ng/g)
is particularly impressive when considering the dissociation
constants (Kd) of TGF-/31 receptors on cultured murine glomer-
ular cells which range from 5to9 M (0.125 to 0.225 ng/ml) [19].
While the precise functions of TGF-f3 within glomeruli are not
defined, two potentially important roles include regulation of
glomerular extracellular matrix metabolism and suppression of
glomerular cell proliferation.
TGF-/3 increases the synthesis of collagen, fibronectin, and
proteoglycans in a number of different cell types [1, 2]. In
addition, TGF-/3 increases the accumulation of proteoglycans
[20], collagen and fibronectin [19] by cultured glomerular
mesangial cells, and increases the production of fibronectin by
glomerular epithelial cells [19]. Given the marked effects of
TGF-p on extracellular matrix synthesis in vitro and the high
concentration of TGF-/3 in the glomerulus in vivo, it is possible
that TGF-/3 plays a role in maintaining basal levels of extracel-
lular matrix component synthesis within the normal glomerulus.
Another role for TGF-/3 in the glomerulus could be to regulate
the proliferation of glomerular cells. We have previously dem-
onstrated that TGF-/3l is a potent inhibitor of mouse glomerular
endothelial, mesangial and epithelial cell proliferation [19].
TGF-/3 could act in vivo to inhibit glomerular cell proliferation,
and thus play a role in the maintenance of the low rate of
proliferation observed in normal glomeruli [21]. The potential
importance of growth inhibitors such as TGF-f3 is suggested by
our finding of potent mitogenic activity in extracts from normal
glomeruli. It seems likely that the low rate of proliferation of
glomerular cells in vivo may result from a careful balance
between growth promoting and growth inhibiting stimuli. Stud-
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ies are currently underway to characterize the mitogenic activ-
ity present in glornerlilar extracts.
The present study does not allow us to determine whether
TGF-/3 in the kidney or glomerulus exists in the active or
biologically latent form, since methods which effectively ex-
tract TGF-/3 from tissue sources (that is, acid-ethanol extrac-
tion) also serve to activate latent forms of TGF-f3. Of interest,
however, is the recent demonstration by Antonelli-Orlidge and
coworkers [22] that co-cultures of bovine adrenal capillary
endothelial cells and bovine aortic smooth muscle cells produce
active TGF-/3. When these cells are cultured alone they make a
latent form of TGF-/3. Glomeruli contain a similar combination
of cell types. Within the glomerulus endothelial cells lie in close
approximation to the smooth muscle cell-like glomerular
mesangial cell [23]. Glomerular endothelial and mesangial cells
could combine, as do bovine aortic smooth muscle cells and
bovine endothelial cells, to produce active TGF-/3 within the
glomerulus.
In this study we also demonstrated the presence of TGF-/32 in
glomeruli. At present it is not known if TGF-/31 and /32 play
different roles within the normal glomerulus. Studies to date
have demonstrated equivalent biological activities of both pep-
tides despite the preferential affinities of cellular receptors for
the different TGF-/3s [8]. We recently identified a unique group
of binding proteins in rat glomeruli which bind TGF-/31 but do
not bind TGF-f32 [24]. Whether these binding proteins play a
role in defining differences in biological activity for the two
peptides is not known.
Since TGF-/3 has such marked effects on growth we also
examined the impact of unilateral nephrectomy on renal TGF-p
expression. Nephrectomy altered TGF-/31 and /32 expression in
glomeruli where marked falls in TGF-/3 mRNA levels occurred
following nephrectomy. However, these falls were not associ-
ated with significant changes in glomerular TGF-/3 protein
levels. The significance of the decline in glomerular TGF-f31 and
/32 mRNA levels following nephrectomy is not known. The
results could be explained if a large fraction of glomerular
TGF-/3 is present in slowly turning over stores, or if a large
fraction of glomerular TGF-f3 is derived from the circulation. If
newly synthesized TGF-/3 has, for unknown reasons, greater
bioactivity than that present in stores, then the falling TGF-/3
mRNA levels might indicate a permissive role for TGF-j3 in the
glomerular growth which follows nephrectomy.
We [19] and others [20] have suggested that TGF-/3 might
play a role in stimulating the accumulation of extracellular
matrix material which occurs in the course of many progressive
glomerular lesions. The finding of large concentrations of
TGF-131 and TGF-132 in the normal glomerulus suggests, how-
ever, that TGF-/3 may have important regulatory functions
under normal conditions as well. These functions could include
the regulation of extracellular matrix metabolism which is so
critical to the maintenance of normal glomerular function, and
actions as an inhibitor of glomerular cell proliferation.
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